Menu Search
Equities

Accendra Health Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6OM:DUS

Accendra Health Inc

Actions
  • Price (EUR)1.91
  • Today's Change-0.09 / -4.50%
  • Shares traded--
  • 1 Year change-75.67%
  • Beta1.3327
Data delayed at least 15 minutes, as of Feb 12 2026 18:32 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Accendra Health, Inc., formerly Owens & Minor, Inc., is a nationwide pure play home-based care platform. Its Patient Direct segment includes home healthcare divisions (Byram and Apria). The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies and is a provider of integrated home healthcare equipment and related services in the United States. It offers a range of products and services for in-home care and delivery, including diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services). Additionally, it supplies a wide range of other home medical equipment, patient care product lines including ostomy, wound care (including negative pressure wound therapy), urology, incontinence and other products and services.

  • Revenue in USD (TTM)6.71bn
  • Net income in USD-410.53m
  • Incorporated1993
  • Employees13.50k
  • Location
    Accendra Health Inc10900 Nuckols Road, Suite 400GLEN ALLEN 23060United StatesUSA
  • Phone+1 (804) 277-4304
  • Fax+1 (804) 723-7100
  • Websitehttps://www.accendrahealth.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.